Oncology and Hematology - Prova Education

Episodes 1-16 of 136

KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Oncology and Hematology
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
- Prof. Markus Hecht
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Oncology and Hematology
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and Hematology
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
- Yungan Tao
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and Hematology
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
- Yungan Tao
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Oncology and Hematology
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Paul L Swiecicki, MD
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
MinuteCE®
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits
MinuteCE®
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  
0.50 credits 3 episodes
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 credits 3 episodes
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
MinuteCE®
Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
1.00 credit 10 episodes
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
- Noopur Raje, MD
1.00 credit 10 episodes
Data Dive: Clinical Evidence Behind CELMoDs
Data Dive: Clinical Evidence Behind CELMoDs
MinuteCE®
Data Dive: Clinical Evidence Behind CELMoDs
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
MinuteCE®
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit
Mastering the Sequence: CELMoDs Across Treatment Lines
Mastering the Sequence: CELMoDs Across Treatment Lines
MinuteCE®
Mastering the Sequence: CELMoDs Across Treatment Lines
1.00 program credit
- Sagar Lonial, MD, FACP
- Noopur Raje, MD
1.00 program credit
Safety First: Navigating CELMoD-Associated Toxicities
Safety First: Navigating CELMoD-Associated Toxicities
MinuteCE®
Safety First: Navigating CELMoD-Associated Toxicities
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit
Why CELMoDs Matter in Myeloma
Why CELMoDs Matter in Myeloma
MinuteCE®
Why CELMoDs Matter in Myeloma
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Next-Generation Innovations: The Future of CELMoDs in Myeloma
MinuteCE®
Next-Generation Innovations: The Future of CELMoDs in Myeloma
1.00 program credit
- Noopur Raje, MD
1.00 program credit

Prev
1
2
3
…
8
9
Next

1/6